Please assess the completion status of the following clinical trial:

Trial Title: Pre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of lymphoblastic lymphoma or acute lymphoblastic leukemia with ≥ 5% blasts in the bone marrow (M2/M3) (with or without extramedullary disease) that meets 1 of the following criteria:~  * Refractory disease/induction failure (failure to achieve initial remission after 2 lines of induction therapy)~ * Relapsed disease (in first relapse or higher)~* Central nervous system (CNS)-positive disease allowed~* Karnofsky performance status (PS) 50-100% (for patients ≥ 16 years of age) OR Lansky PS 50-100% (for patients \< 16 years of age)~* Life expectancy ≥ 8 weeks~* Creatinine clearance ≥ 70 mL/min OR maximum serum creatinine based on age/gender as follows:~  * 0.4 mg/dL (for patients 1 to 5 months of age)~ * 0.5 mg/dL (for patients 6 to 11 months of age)~ * 0.6 mg/dL (for patients 1 year of age)~ * 0.8 mg/dL (for patients 2 to 5 years of age)~ * 1.0 mg/dL (for patients 6 to 9 years of age)~ * 1.2 mg/dL (for patients 10 to 12 years of age)~ * 1.5 mg/dL (males) or 1.4 mg/dL (females) (for patients 13 to 15 years of age)~ * 1.7 mg/dL (males) or 1.4 mg/dL (females) (for patients ≥ 16 years of age)~* ALT \< 5 times upper limit of normal (ULN)~* Total bilirubin ≤ 1.5 times ULN for age~* LVEF ≥ 40% by ECHO/MUGA scan~* Shortening fraction \> 29% by ECHO/MUGA scan~* Able to swallow capsules~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for 2 months after completion of study treatment~* No untreated positive blood cultures or progressive infections as assessed by radiographic studies~* No known allergy to any of the agents or their ingredients used in this study~  * Patients with clinically significant prior allergies to pegaspargase may be treated with asparaginase-Erwinia, if available~* Patients who cannot receive asparaginase on this study (e.g., due to prior pancreatitis, stroke, or other toxicity) are eligible provided they meet all other inclusion/exclusion criteria~* Recovered from prior therapy (defined as CTCAE v3.0 toxicity ≤ grade 1)~* More than 3 weeks since prior chemotherapy for cancer other than hydroxyurea for patients with WBC \> 10,000/mm³~* At least 7 days since prior hematopoietic growth factors (14 days for pegfilgrastim)~* At least 1 month since prior biologic therapy, such as monoclonal antibodies~* At least 3 months since prior hematopoietic stem cell transplantation~Exclusion Criteria:~* Evidence of graft-versus-host disease~* Concurrent valproic acid~* Concurrent coumadin/warfarin other than a short course administered in a prophylactic setting

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Decitabine / Vorinostat (Type: EXPERIMENTAL): This is a therapeutic trial investigating the combination of decitabine 15 mg/m2 and vorinostat 230 mg/m2 (maximum daily dose not to exceed 400 mg) in relapsed/refractory ALL/LL patients prior to induction chemotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues